Beyond the classic angiotensin-receptor-blocker profile (Q37200544)

18 August 2017

1 reference

title

Beyond the classic angiotensin-receptor-blocker profile (English)

1 reference

18 August 2017

Theodore W Kurtz

1

1 reference

18 August 2017

1 July 2008

1 reference

Nature Clinical Practice Cardiovascular Medicine

18 August 2017

1 reference

18 August 2017

5 Suppl 1

1 reference

18 August 2017

S19-26

1 reference

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

18 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

The mechanisms of action of PPARs

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

1 reference

7 January 2021

PPAR(gamma) and glucose homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

The metabolic syndrome--a new worldwide definition

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Retinoid x receptor heterodimers in the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0805

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0805

1 reference

18 August 2017

1 reference

PubMed ID

18580862